Pharmacologic Treatment of Alzheimer-Type Dementia
For mild-to-moderate Alzheimer's disease, initiate treatment with a cholinesterase inhibitor (donepezil, galantamine, or rivastigmine) as first-line therapy, with donepezil being the preferred agent based on its consistent efficacy across all stages of cognitive decline. 1, 2
First-Line Treatment Selection
Start with donepezil as the preferred cholinesterase inhibitor for the following reasons:
- Demonstrates superior efficacy across mild, moderate, and severe cognitive dysfunction compared to other agents 2
- Most extensively studied with high-quality evidence from 24 trials showing statistically significant improvements in ADAS-cog scores and global assessment measures 3
- Better tolerability profile and once-daily dosing improves adherence 4
Alternative first-line cholinesterase inhibitors include galantamine or rivastigmine if donepezil is not tolerated or contraindicated 1, 4.
Dosing Strategy
- Donepezil: Start at 5 mg daily, titrate to 10 mg daily after 4-6 weeks 3
- Continue treatment for at least 6 months before assessing response 4
- Monitor cognitive function (MMSE or ADAS-cog) and global assessment (CIBIC-plus) at 6-month intervals 3
When to Add Memantine
Add memantine to the cholinesterase inhibitor if:
- Inadequate response to monotherapy after 6 months 5
- Disease progresses to moderate severity while on cholinesterase inhibitor 1, 4
- Patient develops behavioral symptoms (agitation, psychosis) that may benefit from dual therapy 1
For moderate-to-severe dementia, combination therapy with a cholinesterase inhibitor plus memantine is recommended as standard treatment 1, 4.
Critical Treatment Thresholds
A clinically meaningful response is defined as:
- ≥4-point improvement on ADAS-cog for mild-to-moderate dementia 3
- ≥3-point improvement on MMSE 3
- Any positive change on CIBIC-plus scale 3
When to Continue vs. Discontinue
Continue treatment if the patient demonstrates:
- Clinically meaningful improvement or stabilization in cognition/function 1
- Reduction in neuropsychiatric symptoms (especially psychosis, agitation, aggression) - continue even if cognitive decline progresses 1
Consider discontinuation only if:
- Clinically meaningful worsening over 6 months despite treatment 1
- No benefit observed at any point during treatment 1
- Severe/end-stage dementia with dependence in most basic ADLs 1
- Intolerable side effects (severe nausea, vomiting, weight loss, falls) 1
Important Caveats
Do not abruptly stop cholinesterase inhibitors in patients with active psychotic symptoms, agitation, or aggression until these stabilize, as withdrawal may precipitate behavioral deterioration 1. If discontinuation is necessary, taper by reducing dose 50% every 4 weeks 1.
The evidence shows that while average improvements may not reach clinically significant thresholds in group analyses, a substantial subset of individual patients achieves meaningful clinical benefit 3. This supports treating individual patients and monitoring their specific response rather than withholding treatment based on population-level statistics.
Emerging disease-modifying therapies (lecanemab, donanemab) are now available for early-stage AD with confirmed amyloid pathology, representing a paradigm shift toward earlier intervention 6. However, cholinesterase inhibitors and memantine remain the standard symptomatic treatments across the disease spectrum.